Bristol-Myers Squibb Company
TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY

Last updated:

Abstract:

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof ("an anti-PD-1 antibody monotherapy"). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

Status:
Application
Type:

Utility

Filling date:

22 Mar 2022

Issue date:

8 Sep 2022